Cefspan

Cefspan may be available in the countries listed below.

Ingredient matches for Cefspan

Cefixime

Cefixime is reported as an ingredient of Cefspan in the following countries:

• Indonesia


• Japan


• Taiwan


• Vietnam

International Drug Name Search

AZ

AZ may be available in the countries listed below.

Ingredient matches for AZ

Azelastine

Azelastine is reported as an ingredient of AZ in the following countries:

• Peru

Azithromycin

Azithromycin dihydrate (a derivative of Azithromycin) is reported as an ingredient of AZ in the following countries:

• Bangladesh

Sodium Bicarbonate

Sodium Bicarbonate is reported as an ingredient of AZ in the following countries:

• Japan

Sodium Gualenate

Sodium Gualenate is reported as an ingredient of AZ in the following countries:

• Japan

International Drug Name Search

Amoxicillina + Acido clavulanico Jet

Amoxicillina + Acido clavulanico Jet may be available in the countries listed below.

Ingredient matches for Amoxicillina + Acido clavulanico Jet

Amoxicillin

Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxicillina + Acido clavulanico Jet in the following countries:

• Italy

Clavulanate

Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Amoxicillina + Acido clavulanico Jet in the following countries:

• Italy

International Drug Name Search

Horizant

Horizant is a brand name of gabapentin, approved by the FDA in the following formulation(s):

HORIZANT (gabapentin enacarbil - tablet, extended release; oral)

• 
  Manufacturer: GLAXO GRP LTD
  
  Approval date: April 6, 2011
  
  Strength(s): 600MG ^[RLD]


• 
  Manufacturer: GLAXO GRP LTD
  
  Approval date: December 13, 2011
  
  Strength(s): 300MG
  

Has a generic version of Horizant been approved?

No. There is currently no therapeutically equivalent version of Horizant available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Horizant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Prodrugs of GABA analogs, compositions and uses thereof
  Patent 6,818,787
  Issued: November 16, 2004
  Inventor(s): Mark A.; Gallop & Kenneth C.; Cundy & Cindy X.; Zhou & Fenmei; Yao & Jia-Ning; Xiang
  Assignee(s): Xenoport, Inc.
  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
  
  Patent expiration dates:
  
  
  • November 6, 2022
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystalline form of γ-aminobutyric acid analog
  Patent 8,026,279
  Issued: September 27, 2011
  Inventor(s): Estrada; Tono & Raillard; Stephen P.
  Assignee(s): XenoPort, Inc.
  A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.
  
  Patent expiration dates:
  
  
  • November 10, 2026
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Prodrugs of GABA analogs, compositions and uses thereof
  Patent 8,048,917
  Issued: November 1, 2011
  Inventor(s): Gallop; Mark A. & Cundy; Kenneth C. & Zhou; Cindy X. & Yao; Fenmei & Xiang; Jia-Ning
  Assignee(s): XenoPort, Inc.
  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
  
  Patent expiration dates:
  
  
  • November 6, 2022
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 6, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Horizant Consumer Information (Drugs.com)
• Horizant Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Horizant Consumer Information (Cerner Multum)
• Gabapentin Consumer Information (Drugs.com)
• Gabapentin Consumer Information (Wolters Kluwer)
• Gabapentin Capsules Consumer Information (Wolters Kluwer)
• Gabapentin Enacarbil Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Gabapentin Solution Consumer Information (Wolters Kluwer)
• Gabapentin Consumer Information (Cerner Multum)
• FusePaq Fanatrex Advanced Consumer Information (Micromedex)
• Gabapentin Advanced Consumer Information (Micromedex)
• Gabapentin AHFS DI Monographs (ASHP)

Doxylin

Doxylin may be available in the countries listed below.

Ingredient matches for Doxylin

Doxycycline

Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Doxylin in the following countries:

• Israel

Doxycycline hydrochloride (a derivative of Doxycycline) is reported as an ingredient of Doxylin in the following countries:

• Australia


• Israel

Doxycycline monohydrate (a derivative of Doxycycline) is reported as an ingredient of Doxylin in the following countries:

• Norway

International Drug Name Search

Azitromicina Dupomar

Azitromicina Dupomar may be available in the countries listed below.

Ingredient matches for Azitromicina Dupomar

Azithromycin

Azithromycin is reported as an ingredient of Azitromicina Dupomar in the following countries:

• Argentina

International Drug Name Search

Blu-Gard

Blu-Gard may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Blu-Gard

Dodecylbenzene Sulfonic Acid

Dodecylbenzene Sulfonic Acid is reported as an ingredient of Blu-Gard in the following countries:

• New Zealand

International Drug Name Search

Herten Plus

Herten Plus may be available in the countries listed below.

Ingredient matches for Herten Plus

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Herten Plus in the following countries:

• Spain

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Herten Plus in the following countries:

• Spain

International Drug Name Search

Viscomucil

Viscomucil may be available in the countries listed below.

Ingredient matches for Viscomucil

Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Viscomucil in the following countries:

• Italy

International Drug Name Search

Cedax

In the US, Cedax (ceftibuten systemic) is a member of the drug class third generation cephalosporins and is used to treat Bladder Infection, Bronchitis, Otitis Media, Pneumonia, Sinusitis, Strep Throat and Tonsillitis/Pharyngitis.

US matches:

• Cedax


• Cedax Suspension

Ingredient matches for Cedax

Ceftibuten

Ceftibuten is reported as an ingredient of Cedax in the following countries:

• Bahrain


• Bulgaria


• Croatia (Hrvatska)


• Ecuador


• Georgia


• Israel


• Italy


• Mexico


• Romania


• Slovakia


• Slovenia


• Spain


• Sweden


• Switzerland

Ceftibuten dihydrate (a derivative of Ceftibuten) is reported as an ingredient of Cedax in the following countries:

• Bangladesh


• Guyana


• Hong Kong


• Hungary


• Malaysia


• Netherlands


• Philippines


• Poland


• Serbia


• Singapore


• Thailand


• United States


• Venezuela

International Drug Name Search

Nalorfina

Nalorfina may be available in the countries listed below.

Ingredient matches for Nalorfina

Nalorphine

Nalorfina (DCIT) is also known as Nalorphine (Rec.INN)

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Remylin

Remylin may be available in the countries listed below.

Ingredient matches for Remylin

Mecobalamin

Mecobalamin is reported as an ingredient of Remylin in the following countries:

• Bangladesh

International Drug Name Search

Fungares

Fungares may be available in the countries listed below.

Ingredient matches for Fungares

Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Fungares in the following countries:

• Indonesia

International Drug Name Search

Dimetapp Allergy Liquigel

Generic Name: brompheniramine (brome feh NEER a meen)

Brand Names: BroveX, BroveX CT, Dimetane, Dimetane Extentab, Dimetapp Allergy, Dimetapp Allergy Liquigel, Lodrane 12 Hour

What is Dimetapp Allergy Liquigel (brompheniramine)?

Brompheniramine is an antihistamine. Brompheniramine blocks the effects of the naturally occurring chemical histamine in the body.

Brompheniramine is used to sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold.

Brompheniramine may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about Dimetapp Allergy Liquigel (brompheniramine)?

Use caution when driving, operating machinery, or performing other hazardous activities. Brompheniramine may cause dizziness or drowsiness. If you experience dizziness or drowsiness, avoid these activities. Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while taking brompheniramine. Do not crush, chew, or break the extended- or timed-release forms of brompheniramine. Swallow them whole. They are specially formulated to release the medication slowly in the body.

What should I discuss with my healthcare provider before taking Dimetapp Allergy Liquigel (brompheniramine)?

Do not take brompheniramine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Before taking brompheniramine, talk to your doctor if you have

• 
  

  glaucoma or increased pressure in the eye;

  
  


• 
  

  a stomach ulcer;

  
  


• 
  

  an enlarged prostate, bladder problems or difficulty urinating;

  
  


• 
  

  an overactive thyroid (hyperthyroidism);

  
  


• 
  

  hypertension or any type of heart problems; or

  
  


• 
  

  asthma.

  
  

You may not be able to take brompheniramine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.

Brompheniramine is in the FDA pregnancy category C. This means that it is not known whether brompheniramine will be harmful to an unborn baby. Do not take brompheniramine without first talking to your doctor if you are pregnant or could become pregnant during treatment. Brompheniramine passes into breast milk. Infants are especially sensitive to the effects of antihistamines, and serious side effects could occur in a nursing infant. Do not take brompheniramine without first talking to your doctor if you are nursing a baby. If you are over 60 years of age, you may be more likely to experience side effects from brompheniramine. You may require a lower dose of this medication.

How should I take Dimetapp Allergy Liquigel (brompheniramine)?

Take brompheniramine exactly as directed on the package or as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Take each dose with a full glass of water.

Brompheniramine can be taken with or without food.

Do not crush, chew, or break the extended- or timed-release forms of brompheniramine. Swallow them whole. They are specially formulated to release the medication slowly in the body.

To ensure that you get a correct dose, measure the liquid form of brompheniramine with a special dose-measuring spoon or cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist where you can get one.

Do not take more of this medication than is prescribed or is recommended on the package. The maximum amount of brompheniramine that you should take in 1 day is 24 mg. The regular-release tablets and the syrup are usually taken every 4 to 6 hours as needed (four to six times a day). The sustained-release tablets and capsules are usually taken every 8 to 12 hours as needed (two or three times a day). If your symptoms do not improve, or if they worsen, contact your healthcare provider. Store brompheniramine at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication unless otherwise directed by your doctor.

What happens if I overdose?

Seek emergency medical attention if an overdose is suspected.

Symptoms of a brompheniramine overdose may include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures.

What should I avoid while taking Dimetapp Allergy Liquigel (brompheniramine)?

Do not take other over-the-counter cough, cold, allergy, diet, pain, or sleep medications while taking brompheniramine without first talking to your pharmacist or doctor. Other medications may also contain brompheniramine or other similar drugs, and you may accidentally take too much of these medicines.

Brompheniramine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if brompheniramine is taken with any of these medications.

Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while taking brompheniramine.

Dimetapp Allergy Liquigel (brompheniramine) side effects

Stop taking brompheniramine and seek emergency medical attention if you experience a rare but serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives).

Other, less serious side effects may be more likely to occur. Continue to take brompheniramine and talk to your doctor if you experience

• 
  

  sleepiness, fatigue, or dizziness;

  
  


• 
  

  headache;

  
  


• 
  

  dry mouth; or

  
  


• 
  

  difficulty urinating or an enlarged prostate.

  
  

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Dimetapp Allergy Liquigel (brompheniramine)?

Do not take brompheniramine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Do not take other over-the-counter cough, cold, allergy, diet, pain, or sleep medications while taking brompheniramine without first talking to your pharmacist or doctor. Other medications may also contain brompheniramine or other similar drugs, and you may accidentally take too much of these medicines.

Brompheniramine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if brompheniramine is taken with any of these medications.

Drugs other than those listed here may also interact with brompheniramine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including vitamins, minerals, and herbal products.

More Dimetapp Allergy Liquigel resources

• Dimetapp Allergy Liquigel Side Effects (in more detail)
• Dimetapp Allergy Liquigel Use in Pregnancy & Breastfeeding
• Dimetapp Allergy Liquigel Drug Interactions
• Dimetapp Allergy Liquigel Support Group
• 0 Reviews · Be the first to review/rate this drug

• Brompheniramine 12-Hour Sustained-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)


• Brompheniramine Professional Patient Advice (Wolters Kluwer)


• Brompheniramine Maleate, Dexbrompheniramine Maleate Monograph (AHFS DI)


• Brovex Suspension MedFacts Consumer Leaflet (Wolters Kluwer)


• Brovex CT Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)


• Lodrane 24 24-Hour Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)


• VaZol Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

Where can I get more information?

• Your pharmacist has more information about brompheniramine written for health professionals that you may read.

See also: Dimetapp Allergy Liquigel side effects (in more detail)

Ceftazidime Kabi

Ceftazidime Kabi may be available in the countries listed below.

Ingredient matches for Ceftazidime Kabi

Ceftazidime

Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Ceftazidime Kabi in the following countries:

• France


• Greece

International Drug Name Search

Xolair

In the US, Xolair (omalizumab systemic) is a member of the drug class other immunosuppressants and is used to treat Asthma, Maintenance.

US matches:

• Xolair

UK matches:

• Xolair 150 mg powder and solvent for solution for injection
• Xolair 150 mg powder and solvent for solution for injection (SPC)

Ingredient matches for Xolair

Omalizumab

Omalizumab is reported as an ingredient of Xolair in the following countries:

• Argentina


• Australia


• Austria


• Belgium


• Brazil


• Canada


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Finland


• France


• Germany


• Hong Kong


• Hungary


• Ireland


• Israel


• Japan


• Mexico


• Netherlands


• New Zealand


• Norway


• Poland


• Portugal


• Singapore


• Slovakia


• Slovenia


• Spain


• Sweden


• Switzerland


• Turkey


• United Kingdom


• United States


• Venezuela

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Bextra

Generic Name: valdecoxib (Oral route)

val-de-KOX-ib

Oral route(Tablet)

Serious skin reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme) have been reported in patients receiving valdecoxib, some resulting in death. Patients appear to be at higher risk for these events during the first 2 weeks of treatment, but these may occur at any time. Valdecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity .

Commonly used brand name(s)

In the U.S.

• Bextra

Available Dosage Forms:

• Tablet

Therapeutic Class: Analgesic

Pharmacologic Class: Cyclooxygenase-2 Inhibitor

Uses For Bextra

Valdecoxib is a non-steroidal anti-inflammatory drug. Nonsteroidal anti-inflammatory drugs (also called NSAIDs) are used to relieve some symptoms caused by arthritis (rheumatism), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure arthritis and will help you only as long as you continue to take it. It may also be used to treat pain associated with menstrual periods.

This medicine was available only with your doctor's prescription.

Valdecoxib was voluntarily withdrawn from the U.S. market on April 7, 2005 due to safety concerns of increased risk of serious heart problems and skin reactions .

Before Using Bextra

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of valdecoxib in children with use in other age groups.

Geriatric

This medicine has been tested and has not been shown to cause different side effects or problems in older people than it does in younger adults.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Desvenlafaxine


• Duloxetine


• Ethinyl Estradiol


• Fluconazole


• Ketoconazole


• Lithium


• Milnacipran


• Norethindrone


• Venlafaxine


• Warfarin

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

• Alcohol abuse (or history of ) or


• Bleeding problems or


• Poor general health or


• Stomach ulcer or other stomach or intestinal problems or


• Tobacco use (or recent history of)—The chance of side effects may be increased.

• Allergy to aspirin or other nonsteroidal anti-inflammatory medicines or


• Asthma with inflammation in the nose (with or without polyps) or with spasm in the breathing tubes caused by aspirin or other non-steroidal anti-inflammatory medicines or


• Skin rash after taking aspirin or NSAIDs—Using valdecoxib with these medicines may cause these problems to become much worse.

• Allergy to sulfonamides (sulfamethoxazole and trimethoprim [e.g., Bactrim, Cotrim], sulfisoxazole [e.g., Gantrisin])—May be at greater risk of serious skin reactions.

• Anemia or


• Dehydration or


• Fluid retention (swelling of feet or lower legs) or


• Heart disease or


• High blood pressure or


• Kidney disease or


• Liver disease—Valdecoxib may make these conditions worse.

• Pain after coronary artery bypass graft (CABG) surgery—Higher risk of serious heart complications and infection in these patients. Valdecoxib should not be used.

Proper Use of Bextra

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

The following section is for information only, since the drug is no longer available.

• Oral dosage form (tablets):
  
  • For dysmenorrhea (pain with your menstrual period)
  
  
  • For osteoarthritis
  
  
  • For rheumatoid arthritis
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using Bextra

If you will be taking this medicine for a long time, it is very important that your doctor check you at regular visits.

Stomach problems may be more likely to occur if you drink alcoholic beverages while being treated with this medicine. Therefore, do not regularly drink alcoholic beverages while taking this medicine, unless otherwise directed by your doctor.

Serious side effects can occur during treatment with this medicine. Sometimes serious side effects can occur without any warning. However, possible warning signs often occur, including swelling of the face, fingers, feet, and/or lower legs; severe stomach pain, black, sticky stools, and/or vomiting of blood or material that looks like coffee grounds; unusual weight gain; and/or skin rash. Stop taking this medicine and check with your doctor immediately if you notice any of these warning signs.

Serious skin reactions can occur during treatment with valdecoxib. Check with your doctor right away if you have any of the following symptoms while taking this medicine: blistering, peeling, loosening of skin, chills, cough, diarrhea, fever, itching, joint or muscle pain, red irritated eyes, red skin lesions, often with a purple center, sore throat, sores, ulcers, white spots in mouth or on lips, or unusual tiredness or weakness.

Check with your doctor immediately if fever, drowsiness, itching of the skin, tiredness, nausea, or stomach pain occurs; these effects may be the first signs of liver toxicity.

Valdecoxib may cause a serious type of allergic reaction called anaphylaxis. Although this is rare, it may occur often in patients who are allergic to aspirin, other nonsteroidal anti-inflammatory drugs, or sulfonamide-type drugs. Anaphylaxis requires immediate medical attention. The most serious signs of this reaction are very fast or irregular breathing, gasping for breath, wheezing, or fainting. Other signs may include changes in color of the skin of the face; very fast but irregular heartbeat or pulse; hive-like swellings on the skin; and puffiness or swellings of the eyelids or around the eyes. If these effects occur, get emergency help at once. Do not try to drive yourself. Call an ambulance, lie down, cover yourself to keep warm, and prop your feet higher than your head. Stay in that position until help arrives.

Bextra Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Less common

• Bloating or swelling of face, arms, hands, lower legs, feet


• blood in urine


• bloody, black, or sticky stools


• blurred vision


• chills


• decreased or painful urination


• dizziness


• fever


• muscle aches and pains


• nausea


• nervousness


• pale skin


• pounding in the ears


• rapid weight gain


• severe stomach pain


• tingling of the hands or feet


• trouble breathing with exertion


• unusual bleeding or bruising


• unusual tiredness or weakness


• vomiting of blood or material that looks like coffee grounds


• yellow eyes or skin

Incidence not known

• Blistering, peeling, loosening of skin


• constipation


• cracks in the skin


• darkened urine


• difficulty swallowing


• fast heartbeat


• hives


• indigestion


• itching


• itching, puffiness, or swelling of the eyelids or around the eyes, face, lips, or tongue


• joint or muscle pain


• large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, sex organs


• loss of appetite


• loss of heat from the body


• nausea


• pains in stomach, side, or abdomen, possibly radiating to the back


• red skin lesions, often with a purple center


• red, irritated eyes


• red, swollen skin


• scaly skin


• shortness of breath


• skin rash


• sores, ulcers, or white spots in mouth or on lips


• tightness in chest


• vomiting


• wheezing


• yellow eyes or skin

Symptoms of overdose

Get emergency help immediately if any of the following symptoms of overdose occur:

• Bloody or black tarry stools


• continuing thirst


• dizziness


• drowsiness


• headache, severe or continuing


• nausea and/or vomiting


• shortness of breath


• stomach pain


• sudden decrease in the amount of urine


• swelling of face, fingers, and/or lower legs


• tightness in chest and/or wheezing


• troubled breathing


• unusual tiredness or weakness


• vomiting of blood or material that looks like coffee grounds


• weight gain

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Acid or sour stomach


• belching


• cough


• diarrhea


• ear congestion


• headache


• heartburn


• indigestion


• sore throat

Less common

• Abdominal fullness


• accidental injury


• back pain


• bloating in the abdomen


• excess gas


• rash


• stuffy or runny nose

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Bextra side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Bextra resources

• Bextra Side Effects (in more detail)
• Bextra Dosage
• Bextra Use in Pregnancy & Breastfeeding
• Drug Images
• Bextra Drug Interactions
• Bextra Support Group
• 9 Reviews for Bextra - Add your own review/rating

• Bextra Prescribing Information (FDA)


• Bextra Consumer Overview

Compare Bextra with other medications

• Osteoarthritis
• Pain
• Period Pain
• Rheumatoid Arthritis

Tarivid Otic Solution

Tarivid Otic Solution may be available in the countries listed below.

Ingredient matches for Tarivid Otic Solution

Ofloxacin

Ofloxacin is reported as an ingredient of Tarivid Otic Solution in the following countries:

• Taiwan

International Drug Name Search

Resinsodio

Resinsodio may be available in the countries listed below.

Ingredient matches for Resinsodio

Polystyrene Sulfonic Acid

Polystyrene Sulfonic Acid sodium salt (a derivative of Polystyrene Sulfonic Acid) is reported as an ingredient of Resinsodio in the following countries:

• Chile


• Singapore


• Spain

International Drug Name Search

Ectomin

Ectomin may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Ectomin

Cypermethrin

Cypermethrin is reported as an ingredient of Ectomin in the following countries:

• South Africa

International Drug Name Search

Lagotran

Lagotran may be available in the countries listed below.

Ingredient matches for Lagotran

Lamotrigine

Lamotrigine is reported as an ingredient of Lagotran in the following countries:

• Argentina

International Drug Name Search

Vancomycin Enterocaps

Vancomycin Enterocaps may be available in the countries listed below.

Ingredient matches for Vancomycin Enterocaps

Vancomycin

Vancomycin hydrochloride (a derivative of Vancomycin) is reported as an ingredient of Vancomycin Enterocaps in the following countries:

• Austria


• Germany

International Drug Name Search

Dolidon

Dolidon may be available in the countries listed below.

Ingredient matches for Dolidon

Caffeine

Caffeine monohydrate (a derivative of Caffeine) is reported as an ingredient of Dolidon in the following countries:

• France

Paracetamol

Paracetamol is reported as an ingredient of Dolidon in the following countries:

• France

International Drug Name Search

Zoom-D

Zoom-D may be available in the countries listed below.

Ingredient matches for Zoom-D

Domperidone

Domperidone is reported as an ingredient of Zoom-D in the following countries:

• India

Omeprazole

Omeprazole is reported as an ingredient of Zoom-D in the following countries:

• India

International Drug Name Search

Doxycycline IPS

Doxycycline IPS may be available in the countries listed below.

Ingredient matches for Doxycycline IPS

Doxycycline

Doxycycline monohydrate (a derivative of Doxycycline) is reported as an ingredient of Doxycycline IPS in the following countries:

• Netherlands

International Drug Name Search

Spirola

Spirola may be available in the countries listed below.

Ingredient matches for Spirola

Spironolactone

Spironolactone is reported as an ingredient of Spirola in the following countries:

• Indonesia

International Drug Name Search

Lescol Prolib

Lescol Prolib may be available in the countries listed below.

Ingredient matches for Lescol Prolib

Fluvastatin

Fluvastatin sodium salt (a derivative of Fluvastatin) is reported as an ingredient of Lescol Prolib in the following countries:

• Spain

International Drug Name Search

SaveHeart

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for SaveHeart

Milbemycin Oxime

Milbemycin Oxime is reported as an ingredient of SaveHeart in the following countries:

• United States

International Drug Name Search

Ciella

Ciella may be available in the countries listed below.

Ingredient matches for Ciella

Salicylic Acid

Salicylic Acid is reported as an ingredient of Ciella in the following countries:

• France

International Drug Name Search

Ronistina

Ronistina may be available in the countries listed below.

Ingredient matches for Ronistina

Betahistine

Betahistine dihydrochloride (a derivative of Betahistine) is reported as an ingredient of Ronistina in the following countries:

• Argentina

International Drug Name Search

Sodium (polystyrène sulfonate de)

Sodium (polystyrène sulfonate de) may be available in the countries listed below.

Ingredient matches for Sodium (polystyrène sulfonate de)

Polystyrene Sulfonic Acid

Sodium (polystyrène sulfonate de) (DCF) is also known as Polystyrene Sulfonic Acid

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Aniracetam

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N06BX11

CAS registry number (Chemical Abstracts Service)

0072432-10-1

Chemical Formula

C12-H13-N-O3

Molecular Weight

219

Therapeutic Category

Nootropic

Chemical Name

2-Pyrrolidinone, 1-(4-methoxybenzoyl)-

Foreign Names

• Aniracetamum (Latin)
• Aniracetam (German)
• Aniracetam (French)
• Aniracetam (Spanish)

Generic Names

• Aniracetam (OS: JAN, USAN)
• Ro 135057 (IS)

Brand Names

• Ampamet
  Menarini, Italy



• Memodrin
  Lavipharm, Greece



• Pergamid
  Pfizer, Argentina

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Procaina Larjan

Procaina Larjan may be available in the countries listed below.

Ingredient matches for Procaina Larjan

Procaine

Procaine hydrochloride (a derivative of Procaine) is reported as an ingredient of Procaina Larjan in the following countries:

• Argentina

International Drug Name Search

Betaglid

Betaglid may be available in the countries listed below.

Ingredient matches for Betaglid

Glimepiride

Glimepiride is reported as an ingredient of Betaglid in the following countries:

• Croatia (Hrvatska)


• Poland


• Slovenia

International Drug Name Search

Divista

Generic Name: chromium picolinate, biotin, pyridoxine, cyanocobalamin, folic acid and omega-3-acid ethyl esters

Dosage Form: capsule
see all prescribing information for Divista

DivistaTM is specially designed as a once a day nutritional adjuvant to the current standard of care for patients with, or at risk of developing type 2 diabetes mellitus (T2DM). DivistaTM provides a method for reducing hyperglycemia and stabilizing the level of serum cholesterol.

DivistaTM is unique in that it utilizes two patented nutritional ingredients, Chromax® (chromium picolinate) and Diachrome® (chromium picolinate and biotin), along with Omega-3 fatty acids to aid in enhancing insulin sensitivity and improve blood sugar metabolism, while promoting healthy lipids and supporting healthy triglyceride levels.

Chromium: is an essential trace mineral required by the human body for normal carbohydrate and lipid metabolism (Wilson and Gondy, 1995). A number of diabetes-like signs and symptoms are seen in chromium deficiency including impaired glucose tolerance, fasting hyperglycemia, glucosuria, elevated circulating insulin and peripheral neuropathy. Dietary chromium intake less than 25% has been reported to adversely affect insulin sensitivity in subjects with mildly impaired glucose tolerance (Anderson, 2000). Over time, urinary chromium losses may contribute to insulin resistance and exacerbate compromised insulin sensitivity in individuals with type 2 diabetes mellitus (T2DM). (Anderson et al., 1991 ; Cefalu and Hu, 2004)

It has been reported that chromium complexes bind to an oligopeptide in order to become biologically active (Davis 1997). The chromium-bound peptide then binds to the insulin receptor and activates tyrosine kinase, amplifying insulin action (Cefalu and Hu, 2004; Wang et al., 2006). In vivo studies have shown that chromium picolinate stimulates intracellular GLUT-4 transporters to translocate from intracellular to the plasma membrane leading to enhanced glucose uptake in muscle cells. (Cefalu et al., 2002, Cefalu and Hu, 2004)

Daily Adequate Intake (AI) of chromium as set by the Institute of Medicine (IOM) is 35 μg for men and 25 μg for women (Food and Nutrition Board (FNB), 2002). A Daily Value (DV) for chromium in food and supplement labels of 120 μg per day was set in 1997 (Trumbo et al.,2001). Based on current research a Tolerable Upper Limit for chromium has not been established by the IOM.

Biotin: is a water-soluble B-complex vitamin necessary for protein, fat and carbohydrate metabolism. It is associated with the proper endogenous production of necessary fatty acids, lymphocytes, digestive enzymes and tissue metabolism. It feces, whereas absorbed amounts of biotin, which exceed the storage capacity of the organism are eliminated in the urine. Shortly after an oral take up of biotin, the biotin concentration in the plasma increases several times, but after 24 h the average value is reached again. In pharmacological dosages (mg-range), biotin stimulates the differentiation of epidermal cells. The effect is independent from the biotin status and influences all keratin structures, like hair, skin and nails.

Recent studies have shown that the elderly with 300 ng/l have a lower biotin level than younger adults and children, whose optimal range lies between 400 and 500 ng/l (Helbich Endermann et al., 1999). The biotin concentration in urine of all age groups is approximately 30 to 40 times higher than the respective serum concentration.

Chromium: Metabolism: The biologically active trivalent state of chromium (Cr3+) is responsible for its nutritional activity. The principal route by which trivalent chromium enters the body is the digestive system. Absorbed chromium circulates as free Cr3+, as Cr3+ bound to transferrin or other plasma proteins (Yamamoto et al. 1987, 1988; Vincent, 2000), or as complexes, such as glucose tolerance factor (GTF) (ATSDR 1998, EPA 1998a). Circulating trivalent chromium can be taken up by tissues, and its distribution in the body depends on the species, age, and chemical form.

The GTF may function by facilitating interaction between insulin and its receptor site, but additional investigations will be required to elucidate the exact mechanisms involved in the essentiality of trivalent chromium. The low molecular weight, chromium-binding complex identified from such sources as bovine milk and rabbit liver has been shown to have in vitro activities comparable to those of GTF with respect to insulin action (Yamamoto et al. 1987, 1988). Chromium is excreted primarily in the urine by glomerular filtration or bound to a low mol-wt organic transporter.

Biotin: Metabolism: Within cells, carboxylases are biotinylated via holocarboxylase synthase, requiring ATP and magnesium. Biotin is recycled from carboxylases via the action of proteolytic enzymes and biotinidase. Biotin is catabolized to a number of metabolites, including bisnorbiotin, biotin sulfoxide, biotin sulfone, and others.

Chromium: Elimination: Absorbed chromium is excreted mainly in the urine; small amounts are lost in hair, perspiration and bile. The 24-hour urinary excretion rates for normal human subjects are reported to be 0.22 μg/day (Gargas et al., 1994), consistent with the relatively low-absorption rate (approximately 0.5%) and typical daily chromium consumption rates (62-85 μg/day) (Anderson et al., 1983).

The tissue distribution, urinary and fecal loss and subcellular hepatocyte distribution and concentration of labels suggest that chromium picolinate has a lifetime of less than 1 day in vivo model. (Hepburn et al., 2002) Half life estimations are based on the three compartment model suggest that elimination from compartment one is relatively fast with a reported half life of seven hours. Elimination from compartments two and three are much slower with reported half lifes of fifteen days and three years respectively. (Gargas, 1994)

Biotin: Elimination: Biotin and biotin metabolites such as bisnorbiotin, biotin-d,l-sulfoxide, bisnorbiotin methyl ketone, and biotin sulfone are excreted in the urine.

There are no reported studies regarding the pharmacokinetic parameters of chromium picolinate or biotin in the geriatric population.

There are no reported studies regarding the pharmacokinetic parameters of chromium picolinate or biotin in the pediatric population.

Chromium: It has been noted that concomitant administration of antacids interferes with chromium absorption whereas aspirin and vitamin C administration potentiate absorption (Ref). However, the overall interference and potentiation of chromium absorption in these cases is minimal and not of clinically relevant concern.

Chromium may compete for one of the binding sites on the iron transport protein, transferrin (Lukaski et al., 1996). Serum iron concentrations and serum ferritin concentrations were unchanged by either resistive training or chromium picolinate supplementation. The high-dose chromium picolinate supplementation for 12 wk did not influence hematologic indexes or indexes of iron metabolism (Campbell, 1997).

Administration of 100 mg vitamin C with 1 mg of chromium resulted in higher plasma levels of chromium than with 1 mg of chromium alone (Food and Nutrition Board, 2001).

Diets high in simple sugars (e.g. sucrose), compared to diets high in complex carbohydrates (e.g. whole grains) increase urinary chromium excretion in adults. This effect may be related is a cofactor required of four enzymes that are involved in carboxylation reactions (acetyl-CoA carboxylase, pyruvate carboxylase, methylcrotonyl-CoA carboxylase, and propionyl- CoA carboxylase) (Dakshinamurti and Cheah-Tan 1968, Dakshinamurti et al., 1970) Biotin has been shown to stimulate hepatic glucokinase, increase pancreatic insulin production through glucokinase mRNA expression and enhance glucose uptake in muscle cells (Spence and Koudelka, 1984, Rodriguez et al., 2001, Trumble et al., 1991). It has been reported that biotin may also decrease expression of phosphoenolpryuvate carboxykinase, an enzyme necessary to down regulate hepatic gluconeogenisis (Dakshinamurti and Li, 1994). In animal and human clinical studies, biotin has been shown to enhance glucokinase activity and lower blood glucose (Romero-Navaro et al., 1999, Furukawa, 1999). Biotin appears to potentiate glucose-induced insulin release but does not appear to directly affect insulin release (Yoshikawa et al., 2002). /Symptoms of overt biotin deficiency include hair loss and a scaly red rash around the eyes, nose, mouth, and genital area. Neurological symptoms in adults have included depression, lethargy, hallucination, and numbness and tingling of the extremities. Individuals with hereditary disorders of biotin metabolism resulting in functional biotin deficiency have evidence of impaired immune system function, including increased susceptibility to bacterial and fungal infections. Zhang et al. (1997) reported low blood biotin levels in 43 non-insulin dependent diabetes mellitus patients with impaired utilization of glucose.

The AI for biotin assumes that current average intakes of biotin (35 mcg to 60 mcg/day) are meeting the dietary requirement (FNB-IOM, 1998). The IOM currently recommends an AI level for biotin of 35-60 μg/day for adults. (Food and Nutrition Board, 2000). The Daily Value (DV) for biotin in food and supplement labels is 300 μg per day. Based on current research a Tolerable Upper Limit for biotin has not been established by the IOM.

Folic Acid: Folic Acid is one of the important hematopoetic agents necessary for proper regeneration of the blood-forming elements and their function. Folic acid is a precursor of a large family of compounds which serve as coenzymes in carbon transfer reactions.

These reactions are required for the synthesis of purine and pyrimidine bases, interconversion of glycine and serine, biosynthesis of methionine methyl groups and degradation of histidine. Additionally, folic acid increases jejunal glycolytic enzymes and is involved in the desaturation and hydroxylation of long-chain fatty acids in the brain. A deficiency in folic acid results in megaloblastic anemia.

DivistaTM (Diachrome® (Chromax® chromium picolinate), Biotin, B6, B12, Folic Acid, Omega-3 Fatty Acids) is a prescription preparation indicated in the adjunctive treatment in patients at risk of developing type 2 diabetes mellitus (T2DM). DivistaTM regulates blood glucose levels, improves insulin sensitivity, and reduces hyperglycemia. DivistaTM is also designed to stabilize serum cholesterol levels to promote cardiovascular health. Optimal results have been observed after 90 days of administration, however improvements may be seen as soon as 30 days. Results will vary depending of the level of glycemic control of the patient at the start of the regimen.

DivistaTM is contraindicated in individuals who are hypersensitive or allergic to any active or inactive ingredients contained in the product including fish or fish oil.

Warning: Ingestion of more than 3 grams of omega-3 fatty acids from fish oils per day may have potential antithrombotic effects, including an increased in bleeding time and INR (international normalized ratio). DHA should be avoided in patients with inherited or acquired bleeding diathesis, including those taking anticoagulants.

Warning: Folic acid alone is improper therapy in the treatment for pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient.

 General: Folic acid in doses above 0.1 mg - 0.4 mg daily may obscure pernicious anemia, in that hematological remission can occur while neurological manifestations remain progressive.

There have been no additional or confirmational reports, nor have there been any substantiated serious adverse events reported by subjects participating in chromium picolinate clinical studies considered related to the product.

As with all nutritional supplements, pregnant or lactating women or individuals with serious health conditions should consult a physician.

Carcinogenesis, mutagenesis, impairment of fertility: Neither chromium picolinatenor biotin has been shown to be mutagenic or carcinogenic in vivo.

Folic acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid.

The oral reference dose (RFD) for chromium, the upper limit of exposure thought to protect high risk populations including infants and pregnant women from toxicity, is 70,000 μg/ day. (Maher, 1999)

 Adults (persons over 12 years of age), one (1) softgel daily, orally, or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.

DivistaTM are opaque blue gelatin softgels imprinted “Divista 110”. Child resistant bottles of 60 softgel capsules. NDC# 52747-110-60. Dispense in a tight, light resistant container as defined by in the USP/NF. Store at room temperature 15° to 30°C (59° to 86° F). Keep in cool, dry place. Softgels are not USP.

Divista  chromium picolinate  capsule

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 52747-110 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CHROMIUM PICOLINATE (CHROMIC CATION) CHROMIUM PICOLINATE 1000 ug BIOTIN (BIOTIN) BIOTIN 2 mg PYRIDOXINE (PYRIDOXINE) PYRIDOXINE 25 mg CYANOCOBALAMIN (CYANOCOBALAMIN) CYANOCOBALAMIN 15 ug FOLIC ACID (FOLIC ACID) FOLIC ACID 1 mg OMEGA-3-ACID ETHYL ESTERS (OMEGA-3-ACID ETHYL ESTERS) OMEGA-3-ACID ETHYL ESTERS 300 mg

Inactive Ingredients Ingredient Name Strength No Inactive Ingredients Found

Product Characteristics Color blue (opaque blue gelatin softgel ) Score no score Shape CAPSULE Size 22mm Flavor Imprint Code Divista;110 Contains

Packaging # NDC Package Description Multilevel Packaging 1 52747-110-60 60 CAPSULE In 1 BOTTLE, PLASTIC None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		07/10/2010

Labeler - US Pharmaceutical Corporation (048318224)

Registrant - US Pharmaceutical Corporation (048318224)

Revised: 01/2010US Pharmaceutical Corporation

More Divista resources

• Divista Side Effects (in more detail)
• Divista Dosage
• Divista Use in Pregnancy & Breastfeeding
• Divista Drug Interactions
• Divista Support Group
• 0 Reviews for Divista - Add your own review/rating

• Divista MedFacts Consumer Leaflet (Wolters Kluwer)


• Animi-3 MedFacts Consumer Leaflet (Wolters Kluwer)


• Fish Oil Consumer Overview


• Lovaza Advanced Consumer (Micromedex) - Includes Dosage Information


• Lovaza MedFacts Consumer Leaflet (Wolters Kluwer)


• Omacor Monograph (AHFS DI)


• Omacor Consumer Overview

Compare Divista with other medications

• ADHD
• Dietary Supplementation
• Hypertriglyceridemia

Exylin

Exylin may be available in the countries listed below.

Ingredient matches for Exylin

Diphenhydramine

Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Exylin in the following countries:

• Bahrain


• Oman

International Drug Name Search

Cesflan

Cesflan may be available in the countries listed below.

Ingredient matches for Cesflan

Pranoprofen

Pranoprofen is reported as an ingredient of Cesflan in the following countries:

• Japan

International Drug Name Search

Altocel

Altocel may be available in the countries listed below.

Ingredient matches for Altocel

Loperamide

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Altocel in the following countries:

• France

International Drug Name Search

Urokinase Vedim

Urokinase Vedim may be available in the countries listed below.

Ingredient matches for Urokinase Vedim

Urokinase

Urokinase is reported as an ingredient of Urokinase Vedim in the following countries:

• Spain

International Drug Name Search

Tatsujipin

Tatsujipin may be available in the countries listed below.

Ingredient matches for Tatsujipin

Benazepril

Benazepril hydrochloride (a derivative of Benazepril) is reported as an ingredient of Tatsujipin in the following countries:

• Japan

International Drug Name Search

Bisoprolol HCT AWD

Bisoprolol HCT AWD may be available in the countries listed below.

Ingredient matches for Bisoprolol HCT AWD

Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Bisoprolol HCT AWD in the following countries:

• Germany

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Bisoprolol HCT AWD in the following countries:

• Germany

International Drug Name Search

Contol

Contol may be available in the countries listed below.

Ingredient matches for Contol

Chlordiazepoxide

Chlordiazepoxide is reported as an ingredient of Contol in the following countries:

• Japan

International Drug Name Search

Diclomax

Diclomax may be available in the countries listed below.

UK matches:

• Diclomax Retard (SPC)
• Diclomax SR (SPC)

Ingredient matches for Diclomax

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclomax in the following countries:

• Bahrain


• Lithuania


• Oman


• United Kingdom

Dicloxacillin

Dicloxacillin sodium salt (a derivative of Dicloxacillin) is reported as an ingredient of Diclomax in the following countries:

• Peru

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Acetaminofén

Acetaminofén may be available in the countries listed below.

Ingredient matches for Acetaminofén

Paracetamol

Paracetamol is reported as an ingredient of Acetaminofén in the following countries:

• Venezuela

International Drug Name Search

Cyclacillin

Cyclacillin may be available in the countries listed below.

Ingredient matches for Cyclacillin

Ciclacillin

Cyclacillin (USAN) is also known as Ciclacillin (Rec.INN)

International Drug Name Search

Glossary

Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Rantin

Rantin may be available in the countries listed below.

Ingredient matches for Rantin

Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Rantin in the following countries:

• Indonesia

International Drug Name Search

Sunatrim

Sunatrim may be available in the countries listed below.

Ingredient matches for Sunatrim

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of Sunatrim in the following countries:

• Ethiopia

Trimethoprim

Trimethoprim is reported as an ingredient of Sunatrim in the following countries:

• Ethiopia

International Drug Name Search

Felsol

Felsol may be available in the countries listed below.

Ingredient matches for Felsol

Fluconazole

Fluconazole is reported as an ingredient of Felsol in the following countries:

• Chile

International Drug Name Search

Estradiol Benzoate

Estradiol Benzoate may be available in the countries listed below.

Ingredient matches for Estradiol Benzoate

Estradiol

Estradiol Benzoate (BANM, JAN) is known as Estradiol in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
JAN	Japanese Accepted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Spironolactonã

Spironolactonã may be available in the countries listed below.

Ingredient matches for Spironolactonã

Spironolactone

Spironolactone is reported as an ingredient of Spironolactonã in the following countries:

• Romania

International Drug Name Search

Ceftazidima Actavis

Ceftazidima Actavis may be available in the countries listed below.

Ingredient matches for Ceftazidima Actavis

Ceftazidime

Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Ceftazidima Actavis in the following countries:

• Italy

International Drug Name Search

Carbocaine

Carbocaine is a brand name of mepivacaine, approved by the FDA in the following formulation(s):

CARBOCAINE (mepivacaine hydrochloride - injectable; injection)

• 
  Manufacturer: HOSPIRA
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 1% ^[RLD][AP], 1.5% ^[RLD][AP], 2% ^[RLD][AP]

Has a generic version of Carbocaine been approved?

Yes. The following products are equivalent to Carbocaine:

mepivacaine hydrochloride injectable; injection

• 
  Manufacturer: WATSON LABS
  
  Approval date: November 20, 1984
  
  Strength(s): 1% ^[AP], 2% ^[AP]

POLOCAINE (mepivacaine hydrochloride injectable; injection)

• 
  Manufacturer: APP PHARMS
  
  Approval date: December 1, 1986
  
  Strength(s): 1% ^[AP], 2% ^[AP]

POLOCAINE-MPF (mepivacaine hydrochloride injectable; injection)

• 
  Manufacturer: APP PHARMS
  
  Approval date: December 1, 1986
  
  Strength(s): 1% ^[AP], 1.5% ^[AP], 2% ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carbocaine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Carbocaine.

See also...

• Carbocaine Consumer Information (Wolters Kluwer)
• Carbocaine Consumer Information (Cerner Multum)
• Mepivacaine Consumer Information (Wolters Kluwer)
• Mepivacaine Consumer Information (Cerner Multum)

Carbon Eczane

Carbon Eczane may be available in the countries listed below.

Ingredient matches for Carbon Eczane

Charcoal

Charcoal, Activated is reported as an ingredient of Carbon Eczane in the following countries:

• Argentina

International Drug Name Search

Gravi-Fol

Gravi-Fol may be available in the countries listed below.

Ingredient matches for Gravi-Fol

Folic Acid

Folic Acid is reported as an ingredient of Gravi-Fol in the following countries:

• Germany

International Drug Name Search

Inalacor Accuhaler

Inalacor Accuhaler may be available in the countries listed below.

Ingredient matches for Inalacor Accuhaler

Fluticasone

Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Inalacor Accuhaler in the following countries:

• Spain

International Drug Name Search

Vitasol A-D3-E

Vitasol A-D3-E may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vitasol A-D3-E

Colecalciferol

Colecalciferol is reported as an ingredient of Vitasol A-D3-E in the following countries:

• Austria

Retinol

Retinol palmitate (a derivative of Retinol) is reported as an ingredient of Vitasol A-D3-E in the following countries:

• Austria

Tocopherol, α-

Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Vitasol A-D3-E in the following countries:

• Austria

International Drug Name Search

Cefalexina Lafedar

Cefalexina Lafedar may be available in the countries listed below.

Ingredient matches for Cefalexina Lafedar

Cefalexin

Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Cefalexina Lafedar in the following countries:

• Argentina

International Drug Name Search

Hestar

Hestar may be available in the countries listed below.

Ingredient matches for Hestar

Hetastarch

Hetastarch is reported as an ingredient of Hestar in the following countries:

• Oman

Pentalamide

Pentalamide is reported as an ingredient of Hestar in the following countries:

• Mexico

International Drug Name Search

Curoxime

Curoxime may be available in the countries listed below.

Ingredient matches for Curoxime

Cefuroxime

Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Curoxime in the following countries:

• Portugal

International Drug Name Search

Mirtazapine Qualimed

Mirtazapine Qualimed may be available in the countries listed below.

Ingredient matches for Mirtazapine Qualimed

Mirtazapine

Mirtazapine is reported as an ingredient of Mirtazapine Qualimed in the following countries:

• France

International Drug Name Search